| abstract |
In this invention, compounds corresponding to formula (I) or a pharmaceutically acceptable salt thereof are described. In formula (I), [D] is the residue of a medicament comprising a reactive functional group, said functional group being fixed, directly or by a group forming a bridge, via an oxyene-phosphorus bond on the phosphorus atom of the fraction (I '), in which R1 represents C1-C8 alkyl, C6-C10 aryl or C7-C12 aralkyl, R2 represents hydrogen, C1-C8 alkyl, C6-C10 aryl, C4-C9 heteroaryl , C3-C7 cycloalkyl, C3-C7 cycloheteroalkyl or C7-C12 aralkyl; and R3 is selected from the group comprising C1-C8 alkyl; C2-C8 alkenyl having one or two double bonds; (C3-C7 cycloalkyl) -CrH2r- in which r is zero, one, two or three, the cycloalkyl part not being substituted or carrying 1 or 2 C1-C4 alkyl substituents on the ring part; (C6-C10 aryloxy) C1-C8 alkyl; 2-, 3- or 4- pyridyl; and phenyl -CrH2r- in which r is zero, one, two or three and in which the phenyl is unsubstituted, or is substituted by 1 to 3 alkyls each having from 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms, halo, trifluoromethyl, dialkylamino having 2 to 8 carbon atoms or alkanoxylamino having 2 to 6 carbon atoms. The compounds of this invention are suitable for targeted delivery of drugs, more particularly to the brain. |